wherein each alkyl or cycloalkyl group is optionally independently substituted with one to three F atoms or with one CN or one OH, and

wherein each heterocyclyl group is selected from a group consisting of oxetanyl, azetidinyl, pyrrolidinyl, morpholinyl and 1,4-diazepan-5-one, and

wherein each heterocyclyl group is optionally substituted with 1 or 2 substituents independently selected from F, OH and CH_3, and

wherein each heteroaryl group is selected from a group consisting of furanyl and thiazolyl.

6. A compound of formula (I) according to claim 5, wherein

R^2 is independently selected from the group consisting of:

F, Cl, Br, -CN, -CF_3,  , -O-CH_3, -O-CHF_2, -O-CH_2-CH_2-F, -O-CH_2-CHF_2, -O-CH_2-CF_3, -O-CH_2-CH_2-CH_2-F, -O-CH_2-CF_2-CH_3,  ,  ,  , -S-CH_3, -NH_2, -NH-CH_2-CH_2-CH_2-F, -NH-CH_2-CH_2-CHF_2,  ,  ,  ,  ,  ,



7. A compound of formula (I) according to any one of the previous claims, wherein X is CH.

8. A compound of formula (I) according to any one of the previous claims, wherein X is N.

9. A compound according to claim 1 having the formula



(I.2)

wherein

R^1 is CH_3;

R^{2a} and R^{2b} are each independently selected from the group consisting of:

H, F, Cl, Br, -CN, $-CF_3$,  , $-O-CH_3$, $-O-CHF_2$, $-O-CH_2-CH_2-F$, $-O-CH_2-CHF_2$, $-O-CH_2-CF_3$, $-O-CH_2-CH_2-CH_2-F$, $-O-CH_2-CF_2-CH_3$,  ,  ,


, -S-CH_3, -NH_2, -NH-CH_2-CH_2-CH_2-F, -NH-CH_2-CH_2-CHF_2, 

, 
, 
, 
, 
, 
, 
, 
, 
, 
, 
, 
and 
; and

with the proviso that only one of R^{2a} and R^{2b} is H;

or a salt thereof.

10. A compound according to claim 1 selected from:


, 
,


,

,

and

,

or a salt thereof.

11. The compound according to claim 10, wherein said compound is:


.

12. The compound according to claim 10, wherein said compound is:


.

13. The compound according to claim 10, wherein said compound is:


.

14. The compound according to claim 10, wherein said compound is:



.

15. The compound according to claim 10, wherein said compound is:



.

16. The compound according to claim 10, wherein said compound is:



.

17. The compound according to claim 10, wherein said compound is:



.

18. The compound according to claim 10, wherein said compound is:



.

19. The compound according to claim 10, wherein said compound is:



.

20. The compound according to claim 10, wherein said compound is:



.

21. The compound according to claim 10, wherein said compound is:



.

22. The compound according to claim 10, wherein said compound is:



.

23. The compound according to claim 10, wherein said compound is:



.

24. The compound according to claim 10, wherein said compound is:



.

25. The compound according to claim 10, wherein said compound is:



.

26. The compound according to claim 10, wherein said compound is:



.

27. The compound according to claim 10, wherein said compound is:



.

28. The compound according to claim 10, wherein said compound is:



.

29. A pharmaceutically acceptable salt of a compound according to any one of claims 1 to 28.

30. A compound according to any one of claims 1 to 28 or a pharmaceutically acceptable salt thereof for use as a medicament.

31. A compound according to any one of claims 1 to 28 or a pharmaceutically acceptable salt thereof for use in treating obesity, type 2 diabetes mellitus, insulin resistance and/or obsesity in patients suffering from Prader-Willi-Syndrome.

32. A pharmaceutical composition comprising a compound according to any one of claims 1 to 28 or a pharmaceutically acceptable salt thereof, optionally together with one or more inert carriers and/or diluents.

33. Use of a compound according to any one of claims 1 to 28 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease or condition which is mediated by inhibiting the activity of the ghrelin O-acyl transferase (GOAT).

34. A pharmaceutical composition comprising one or more compounds according to one or more of the claims 1 to 28 or a pharmaceutically acceptable salt thereof and one or more additional therapeutic agents, optionally together with one or more inert carriers and/or diluents.

35. Use of a compound according to any one of claims 1 to 28 or a pharmaceutically acceptable salt thereof for the prepation of a medicament for treating obesity, including obesity in patients suffering from Prader-Willi-Syndrome, type 2 diabetes mellitus or insulin resistance.